Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2011

View Archived Issues

Researchers describe discovery and development of hepatitis C treatment GS-5885

Scientists present two new agents against herpes simplex virus

FDA approves use of Edurant in treatment-naive adults with HIV-1

PMX-30063 shows activity against oral mucositis in animal study

PRM-151 is safe and active in healthy volunteers and in subjects with idiopathic pulmonary fibrosis

PF-4357415 is superior to fluticasone propionate in rat model of lung inflammation

Phase II data disclosed on tanezumab in chronic prostatitis/chronic pelvic pain syndrome

First patients enrolled in phase I trial of Glycotope's FSH-GEX

Thermo Fisher Scientific signs definitive agreement to acquire Phadia

Novartis confirms new divisional structure following merger with Alcon

Themis Bioscience raises funds to advance vaccine candidates

New delta opioid receptor antagonists reported by Janssen group

KIST presents novel protein kinase inhibitors for cancer

Merck & Co. describes new phosphodiesterase 10A inhibitors

New closthioamides presented

Scientists prepare new adenosine A2A receptor antagonists

Sosei launches NorLevo emergency contraceptive pill in Japan

FDA approves Incivek for genotype 1 chronic hepatitis C

Nexavar plus standard chemotherapy improves progression-free survival of patients with breast cancer

Genentech reports phase II data on MetMAb/Tarceva in NSCLC

Gactiv approved in Japan for type 2 diabetes in combination with alpha-glucosidase inhibitors

VivaGel is efficacious in phase II trial in bacterial vaginosis

Abbott to submit ALK FISH test for approval in Japan and U.S.

Daiichi Sankyo and AstraZeneca enter copromotion agreement for denosumab in Japan

EMA's CHMP recommends label extension for tocilizumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...